Special Issue

Novel Strategies to Combat MDR Pathogens in CF

Message from the Guest Editor

Cystic fibrosis (CF) is characterized by a chronic cycle of airway obstruction, inflammation, and infection. The introduction of highly active CFTR modulator therapies has resulted in significant improvements in clinical outcomes in people with CF; however, chronic lung infections persist. Complicating treatment is the presence of multidrug-resistant (MDR) pathogens which contribute to decline in lung function and shortened survival. In this Special Issue, novel strategies to combat MDR pathogens will be investigated. The use of adjuvants targeting resistance (e.g., inactivating enzymes, antibiotic efflux, permeation) and virulence (e.g., biofilm, iron sequestration) as well as novel antimicrobial therapies including antimicrobial peptides and bacteriophages will be considered. In addition, approaches incorporating pharmacokinetics and pharmacodynamics to optimize antimicrobial dosing and the use of combination therapy to target MDR pathogens are encouraged.

Guest Editor

Prof. Dr. Paul M. Beringer

Department of Clinical Pharmacy, University of Southern California, Los Angeles, CA 90089-9121, USA

Deadline for manuscript submissions

closed (28 February 2022)

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/si/77335

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/journal/antibiotics

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

MDPI